IAP antagonists induce anti-tumor immunity in multiple myeloma

@article{Chesi2016IAPAI,
  title={IAP antagonists induce anti-tumor immunity in multiple myeloma},
  author={Marta Chesi and Noweeda N Mirza and Victoria M Garbitt and Meaghen E Sharik and Amylou C Dueck and Yan W. Asmann and Ilseyar Akhmetzyanova and Heidi E. Kosiorek and Arianna Calcinotto and Daniel L. Riggs and Niamh Keane and Gregory J. Ahmann and Kevin M Morrison and Rafael Fonseca and Martha Q. Lacy and David Dingli and Shaji K Kumar and Sikander Ailawadhi and Angela Dispenzieri and Francis K Buadi and Morie A Gertz and Craig B. Reeder and Yi Lin and Asher Alban Chanan-Khan and Alexander Stewart and David Robert Fooksman and P Leif Bergsagel},
  journal={Nature Medicine},
  year={2016},
  volume={22},
  pages={1411-1420}
}
The cellular inhibitors of apoptosis (cIAP) 1 and 2 are amplified in about 3% of cancers and have been identified in multiple malignancies as being potential therapeutic targets as a result of their role in the evasion of apoptosis. Consequently, small-molecule IAP antagonists, such as LCL161, have entered clinical trials for their ability to induce tumor necrosis factor (TNF)-mediated apoptosis of cancer cells. However, cIAP1 and cIAP2 are recurrently homozygously deleted in multiple myeloma… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 46 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 65 references

Similar Papers

Loading similar papers…